Antiviral therapy for enteroviruses and rhinoviruses - PubMed (original) (raw)

Review

Antiviral therapy for enteroviruses and rhinoviruses

H A Rotbart. Antivir Chem Chemother. 2000 Jul.

Free article

Abstract

The picornaviruses are a diverse group of viral pathogens that together comprise the most common causes of infection of humans in the developed world. Within the picornavirus family are three well-known groups of human pathogens--the rhinoviruses, the enteroviruses (including polioviruses, coxsackieviruses and echoviruses) and the hepatoviruses (including hepatitis A virus). This article will focus on the rhinoviruses and enteroviruses, agents for which substantial effort has been expended, and recent successes reported, toward the development of safe and effective antiviral therapy.

PubMed Disclaimer

Similar articles

• Treatment of picornavirus infections.
  Rotbart HA. Rotbart HA. Antiviral Res. 2002 Feb;53(2):83-98. doi: 10.1016/s0166-3542(01)00206-6. Antiviral Res. 2002. PMID: 11750935 Review.
• Antiviral agents against picornaviruses.
  Eggers HJ. Eggers HJ. Antiviral Res. 1985;Suppl 1:57-65. doi: 10.1016/s0166-3542(85)80009-7. Antiviral Res. 1985. PMID: 3002267 Review. No abstract available.
• Picornavirus infections: a primer for the practitioner.
  Rotbart HA, Hayden FG. Rotbart HA, et al. Arch Fam Med. 2000 Sep-Oct;9(9):913-20. doi: 10.1001/archfami.9.9.913. Arch Fam Med. 2000. PMID: 11031400 Review.
• Recent advances in the treatment of rhinovirus infections.
  McKinlay MA. McKinlay MA. Curr Opin Pharmacol. 2001 Oct;1(5):477-81. doi: 10.1016/s1471-4892(01)00083-2. Curr Opin Pharmacol. 2001. PMID: 11764773 Review.
• Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment.
  McKinlay MA, Pevear DC, Rossmann MG. McKinlay MA, et al. Annu Rev Microbiol. 1992;46:635-54. doi: 10.1146/annurev.mi.46.100192.003223. Annu Rev Microbiol. 1992. PMID: 1332585 Review.

Cited by

• Tanomastat exerts multi-targeted inhibitory effects on viral capsid dissociation and RNA replication in human enteroviruses.
  Lim TYM, Jaladanki CK, Wong YH, Yogarajah T, Fan H, Chu JJH. Lim TYM, et al. EBioMedicine. 2024 Sep;107:105277. doi: 10.1016/j.ebiom.2024.105277. Epub 2024 Sep 2. EBioMedicine. 2024. PMID: 39226680 Free PMC article.
• Antiviral Mechanisms of Saucerneol from Saururus chinensis against Enterovirus A71, Coxsackievirus A16, and Coxsackievirus B3: Role of Mitochondrial ROS and the STING/TKB-1/IRF3 Pathway.
  Song JH, Mun SH, Yang H, Kwon YS, Kim SR, Song MY, Ham Y, Choi HJ, Baek WJ, Cho S, Ko HJ. Song JH, et al. Viruses. 2023 Dec 21;16(1):16. doi: 10.3390/v16010016. Viruses. 2023. PMID: 38275951 Free PMC article.
• Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5.
  Lane TR, Fu J, Sherry B, Tarbet B, Hurst BL, Riabova O, Kazakova E, Egorova A, Clarke P, Leser JS, Frost J, Rudy M, Tyler KL, Klose T, Volobueva AS, Belyaevskaya SV, Zarubaev VV, Kuhn RJ, Makarov V, Ekins S. Lane TR, et al. Antiviral Res. 2023 Aug;216:105654. doi: 10.1016/j.antiviral.2023.105654. Epub 2023 Jun 14. Antiviral Res. 2023. PMID: 37327878 Free PMC article.
• Therapeutics for fulminant hepatitis caused by enteroviruses in neonates.
  Wang LC, Tsai HP, Chen SH, Wang SM. Wang LC, et al. Front Pharmacol. 2022 Oct 20;13:1014823. doi: 10.3389/fphar.2022.1014823. eCollection 2022. Front Pharmacol. 2022. PMID: 36339581 Free PMC article. Review.
• Targeting the Virus Capsid as a Tool to Fight RNA Viruses.
  Hozáková L, Vokatá B, Ruml T, Ulbrich P. Hozáková L, et al. Viruses. 2022 Jan 18;14(2):174. doi: 10.3390/v14020174. Viruses. 2022. PMID: 35215767 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database